An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and neck squamous cell carcinoma unsuitable for surgery and radiotherapy and without distant metastases

Trial Profile

An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and neck squamous cell carcinoma unsuitable for surgery and radiotherapy and without distant metastases

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Fimaporfin (Primary) ; Bleomycin
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors PCI Biotech
  • Most Recent Events

    • 08 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 22 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 22 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top